{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:01:49Z","timestamp":1790226109342,"version":"4.1.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Down syndrome (DS) is the most common cancer predisposing syndrome (CPS) associated with a markedly increased risk of pediatric hematologic malignancies, specifically acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Although both AML and ALL occur more frequently in children with DS than in the general pediatric population, the sequential development of both malignancies in the same patient is extremely rare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Here we report the case of a child with DS who initially developed an AML and subsequentially an ALL, while the myeloid leukemia was in remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This case underscores the rarity of sequential AML and ALL in DS patients and supports the hypothesis that these leukemias represent biologically distinct diseases. Trisomy 21 has a central role in predisposing to both myeloid and lymphoid leukemogenesis through profound alterations of hematopoiesis and gene deregulation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1937872","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:36:47Z","timestamp":1790224607000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A cancer-predisposing syndrome is always there: a sequential occurrence of acute lymphoblastic leukemia after acute myeloid leukemia in a child with down syndrome"],"prefix":"10.3389","volume":"16","author":[{"given":"Marta","family":"Arrabito","sequence":"first","affiliation":[{"name":"PhD program; Med-Clin Department; University of Catania","place":["Catania, Italy"]},{"name":"Center of Pediatric Hematology Oncology Azienda Ospedaliero Universitaria Policlinico \u2013 San Marco","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Li Volsi","sequence":"additional","affiliation":[{"name":"Center of Pediatric Hematology Oncology Azienda Ospedaliero Universitaria Policlinico \u2013 San Marco","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Cannata","sequence":"additional","affiliation":[{"name":"Cytogenetic-Cytofluorimetric-Molecular Biology Lab, Center of Pediatric Hematology Oncology, Azienda Policlinico \u2013 San Marco","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"La Rosa","sequence":"additional","affiliation":[{"name":"Center of Pediatric Hematology Oncology Azienda Ospedaliero Universitaria Policlinico \u2013 San Marco","place":["Catania, Italy"]},{"name":"Cytogenetic-Cytofluorimetric-Molecular Biology Lab, Center of Pediatric Hematology Oncology, Azienda Policlinico \u2013 San Marco","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Lo Nigro","sequence":"additional","affiliation":[{"name":"Center of Pediatric Hematology Oncology Azienda Ospedaliero Universitaria Policlinico \u2013 San Marco","place":["Catania, Italy"]},{"name":"Cytogenetic-Cytofluorimetric-Molecular Biology Lab, Center of Pediatric Hematology Oncology, Azienda Policlinico \u2013 San Marco","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1706537","article-title":"Down syndrome","volume":"382","author":"Bull","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022247","article-title":"Landscape of driver mutations and their clinical effects on Down syndrome\u2013related myeloid neoplasms","volume":"143","author":"Sato","year":"2024","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(99)05264-2","article-title":"Risks of leukaemia and solid tumours in individuals with Down\u2019s syndrome","volume":"355","author":"Hasle","year":"2000","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.749480","article-title":"Ten reasons why people with Down syndrome are protected from the development of most solid tumors -A review","volume":"12","author":"Osuna-Marco","year":"2021","journal-title":"Front Genet"},{"key":"B5","article-title":"Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children\u2019s Cancer Group Studies 2861 and 2891","volume":"91","author":"Lange","year":"1998","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03929-x","article-title":"Blood and immune development in human fetal bone marrow and Down syndrome","volume":"598","author":"Jardine","year":"2021","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.636633","article-title":"Molecular mechanisms of the genetic predisposition to acute megakaryoblastic leukemia in infants with Down syndrome","volume":"11","author":"Grimm","year":"2021","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133265","article-title":"Myeloid leukemia of Down syndrome","volume":"15","author":"Kosmidou","year":"2023","journal-title":"Cancers"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-016-0338-x","article-title":"Transient abnormal myelopoiesis and AML in Down syndrome: an update","volume":"11","author":"Bhatnagar","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ccell.2019.08.014","article-title":"Mechanisms of progression of myeloid preleukemia to transformed myeloid leukemia in children with Down syndrome","volume":"36","author":"Labuhn","year":"2019","journal-title":"Cancer Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-491936","article-title":"Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome","volume":"122","author":"Nikolaev","year":"2013","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025032083","article-title":"Polycomb repressive complex 2 insufficiency underlies myeloid leukemia in Down syndrome","volume":"148","author":"Suzuki","year":"2026","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2013-07-453480","article-title":"How I treat ALL in Down\u2019s syndrome: pathobiology and management","volume":"123","author":"Izraeli","year":"2014","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-509463","article-title":"Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group","volume":"123","author":"Buitenkamp","year":"2014","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1038\/ncomms5654","article-title":"Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations","volume":"5","author":"Nikolaev","year":"2014","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-01357","article-title":"Reducing daunorubicin in induction therapy in children with B-lineage ALL with favorable prognosis: Results of phase III trial AIEOP-BFM ALL 2009","volume":"43","author":"Gottschalk","year":"2025","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26411","article-title":"Acute lymphoblastic leukemia in patients with Down syndrome with a previous history of acute myeloid leukemia","volume":"64","author":"Tomizawa","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/01.mph.0000172223.04694.c4","article-title":"GATA1 mutation analysis demonstrates two distinct primary leukemias in a child with Down syndrome; implications for leukemogenesis","volume":"27","author":"Hellebostad","year":"2005","journal-title":"J Pediatr Hematol\/Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1542\/peds.18.4.643","article-title":"Development of acute lymphoblastic leukemia following treatment for acute myeloid leukemia in children with Down syndrome: a case report and retrospective review of Children\u2019s Oncology Group acute myeloid leukemia trials","volume":"66","author":"Murphy","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v65.6.1364.bloodjournal6561364","article-title":"Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases","volume":"65","author":"Michels","year":"1985","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.24287\/1726-1708-2015-14-3-13-33","article-title":"Haematopoietic development and leukaemia in Down syndrome","volume":"167","author":"Roberts","year":"2014","journal-title":"Br J Haematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0854-5","article-title":"Gain of chromosome 21 in hematological Malignancies: lessons from studying leukemia in children with Down syndrome","volume":"34","author":"Laurent","year":"2020","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283225","article-title":"Down syndrome and leukemia: from basic mechanisms to clinical advances","volume":"108","author":"Baruchel","year":"2023","journal-title":"Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008124","article-title":"Gata1s mutant mice display persistent defects in the erythroid lineage","volume":"7","author":"Ling","year":"2023","journal-title":"Blood Adv"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101154","article-title":"Down syndrome and leukemia: An insight into the disease biology and current treatment options","volume":"64","author":"Barwe","year":"2024","journal-title":"Blood Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14085","article-title":"Supportive care utilization and treatment toxicity in children with Down syndrome and acute lymphoid leukaemia at free\u2010standing paediatric hospitals in the United States","volume":"174","author":"Salazar","year":"2016","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.1.245","article-title":"Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome","volume":"99","author":"Zwaan","year":"2002","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/01.cad.0000198911.98442.16","article-title":"Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia","volume":"17","author":"Palle","year":"2006","journal-title":"Anti-Cancer Drugs"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12012-015-9307-1","article-title":"Anthracycline-related cardiotoxicity in patients with acute myeloid leukemia and Down syndrome: a literature review","volume":"16","author":"Hefti","year":"2016","journal-title":"Cardiovasc Toxicol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/mph.0000000000000540","article-title":"Pharmacokinetics of chemotherapeutic drugs in pediatric patients with Down syndrome and leukemia","volume":"38","author":"Hefti","year":"2016","journal-title":"J Pediatr Hematol\/Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25917","article-title":"Infectious complications in children with acute myeloid leukemia and Down syndrome: analysis of the prospective multicenter trial AML\u2010BFM 2004","volume":"63","author":"Hassler","year":"2016","journal-title":"Pediatr Blood Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1937872\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:36:55Z","timestamp":1790224615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1937872\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":32,"alternative-id":["10.3389\/fonc.2026.1937872"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1937872","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"1937872"}}